Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression

Journal of Clinical Psychopharmacology

Volumn 20, Issue 6, 2000, Pages 658-665

  Ackerman, Deborah L ^a   Greenland, Sander ^a   Bystritsky, Alexander ^b   Small, Gary W ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PLACEBO;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GERONTOPSYCHIATRY; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE;

AGED; CONFIDENCE INTERVALS; DEPRESSION; FEMALE; FLUOXETINE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PLACEBO EFFECT; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 0033696554     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200012000-00012     Document Type: Article

References (46)

1. Biological heterogeneity and psychiatric research
2. Mixture distributions in psychiatric research
3. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group
4. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression
5. Predicting response to fluoxetine in geriatric patients with major depression
6. Characteristics of fluoxetine vs. placebo responders in a randomized trial of geriatric depression
7. Use of pattern analysis to identify true drug response: A replication
8. Heterogeneity of clinical response during placebo treatment
9. Different types of placebo response in patients receiving antidepressants
10. Further evidence that a placebo response to antidepressants can be identified
11. Review of the use of pattern analysis to differentiate true drug and placebo responses
12. The double-blind in danger: Untoward consequences of informed consent
13. Inert placebo versus active medication. Patient blindability in clinical pharmacological trials
14. Baseline characteristics of 10-day placebo washout responders in antidepressant trials
15. Side effects and the 'blindability' of clinical drug trials
16. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A quantitative review
17. Paradoxical influence of therapeutic side-effect interpretation
18. Doctor medication guesses: An indicator of clinical improvement in double-blind studies - A contribution to the methodology of psychiatric drug evaluation
19. Side reactions on meprobamate and placebo
20. Is a double-blind clinical trial really double-blind? A report of doctors' medication guesses
21. Physiologic responses as prognostic guides in the used of antidepressant drugs
22. Depressive subtypes, blood pressure changes and response to treatment
23. Relationship between early side effects and therapeutic effects of clomipramine therapy in OCD
24. Side effects as predictors of drug response in OCD
25. Somatic symptoms in depression and antidepressants
26. Site variability in a multisite geriatric depression trial
27. A rating scale for depression
28. Nonspecific effects in longitudinal studies: Impact on quality of life measures
29. Placebo and placebo effect: Their impact on the evaluation of drug response in patients
30. The outcome problem in psychotherapy: What have we learned?
31. Is there a difference between elderly and younger patients with regard to the symptomatology and aetiology of depression?
32. Anxiety as a predictor of response to interpersonal psychotherapy for recurrent major depression: An exploratory investigation
33. How long to onset of antidepressant action: A meta-analysis of patients treated with fluoxetine or placebo
34. The impact of somatic morbidity on the Hamilton Depression Rating Scale in the very old
35. Exactly what does the Hamilton Depression Rating Scale measure?
36. Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication
37. Listening to meta-analysis but hearing bias
38. Listening to Prozac and hearing noise: Commentary on Kirsch and Saperstein's 'Listening to Prozac but hearing placebo'
39. Commentary on Kirsch and Saperstein
40. Growing placebo response rate: The problem in recent therapeutic trials?
41. Placebo response in anxiety disorders
42. Meta-analysis of trials comparing antidepressants with placebos
43. Somatic symptoms: A major feature of depression in a family practice
44. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo